<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04465877</url>
  </required_header>
  <id_info>
    <org_study_id>AT662-U-20-003</org_study_id>
    <nct_id>NCT04465877</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability, Pharmacokinetics &amp; Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes</brief_title>
  <official_title>Single-blind, Randomized, Placebo-controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JTT-662 Administered for 28 Days in Subjects With Type 2 Diabetes Mellitus on Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akros Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akros Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
      JTT-662 administered once daily for 28 days in subjects with Type 2 diabetes mellitus (T2DM)
      who are receiving metformin monotherapy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in postprandial glucose (PPG) area under the observed effect-time curve from the start of breakfast until the 4-hour time point (AUEC0-4) compared to placebo</measure>
    <time_frame>Days 1, 14 and 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>JTT-662 maximum plasma concentrations</measure>
    <time_frame>Days 1, 14 and 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>JTT-662 trough plasma concentrations</measure>
    <time_frame>6 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>6 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of blood pressure</measure>
    <time_frame>6 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of heart rate</measure>
    <time_frame>6 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of body temperature</measure>
    <time_frame>6 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stool diary to assess date, time and type of stool for each stool during the study</measure>
    <time_frame>6 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>JTT-662 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JTT-662 Tablets Dose 1 by mouth once daily from Day 1 to Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JTT-662 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JTT-662 Tablets Dose 2 by mouth once daily from Day 1 to Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JTT-662 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JTT-662 Tablets Dose 3 by mouth once daily from Day 1 to Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Tablets by mouth once daily from Day 1 to Day 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JTT-662</intervention_name>
    <description>Active drug tablets containing JTT-662</description>
    <arm_group_label>JTT-662 Dose 1</arm_group_label>
    <arm_group_label>JTT-662 Dose 2</arm_group_label>
    <arm_group_label>JTT-662 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets matching in appearance to the active drug tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of T2DM for at least 12 weeks prior to the Screening Visit

          -  Currently treated with a stable oral dose of metformin for at least 12 weeks prior to
             the Screening Visit

          -  Have a glycosylated hemoglobin (HbA1c) value of between 6.5% and 10.0% at the
             Screening Visit

          -  Have a fasting plasma glucose (FPG) value of no more than 280 mg/dL at the Screening
             Visit and on Day -3

          -  Body Mass Index (BMI) of 25 to 40 kg/m2 (inclusive)

          -  Must be willing to wear a continuous glucose monitor (CGM) device

        Exclusion Criteria:

          -  Known medical history or presence of Type 1 diabetes mellitus, Maturity Onset Diabetes
             of the Young or secondary forms of diabetes

          -  Known medical history or presence of diabetic complications

          -  Have taken anti-diabetic medications (other than metformin) or medications that act
             mainly in the gastrointestinal tract (e.g., orlistat, acarbose) within 12 weeks prior
             to the Screening Visit or from the Screening Visit to Day -3

          -  Have uncontrolled hypertension (systolic blood pressure of at least 160 mmHg or
             diastolic blood pressure of at least 95 mmHg) at the Screening Visit

          -  Have impaired renal function (estimated glomerular filtration rate (eGFR) &lt;60
             mL/min/1.73 m2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shunsuke Fujii</last_name>
    <phone>609-919-9570</phone>
    <email>ClinicalTrials@akrospharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qps-Mra, Llc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akros Pharma Inc.</last_name>
      <email>ClinicalTrials@akrospharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>JTT-662</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

